Com­pass Path­ways' Phase IIb psilo­cy­bin tri­al shows re­duced de­pres­sion symp­toms

UK biotech Com­pass Path­ways re­vealed this morn­ing that they reached the pri­ma­ry end­point in a Phase IIb clin­i­cal tri­al of psilo­cy­bin ther­a­py.

In the ran­dom­ized, con­trolled and dou­ble-blind tri­al, in­ves­ti­ga­tors looked at a sin­gle dose of Com­pass’s in­ves­ti­ga­tion­al psilo­cy­bin ther­a­py COMP360 for treat­ment-re­sis­tant de­pres­sion in 233 pa­tients, giv­en along­side psy­cho­log­i­cal sup­port. The tri­al, which had all pa­tients stop­ping an­ti­de­pres­sants be­fore par­tic­i­pat­ing, com­pared two ac­tive dos­es of COMP360, 25mg and 10mg, against a com­para­tor 1mg dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER